The stock of Ascendis Pharma A S (NASDAQ:ASND) hit a new 52-week high and has $41.00 target or 100.00% above today’s $20.50 share price. The 5 months bullish chart indicates low risk for the $498.87 million company. The 1-year high was reported on Oct, 17 by Barchart.com. If the $41.00 price target is reached, the company will be worth $498.87 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 107,149 shares traded hands or 163.86% up from the average. Ascendis Pharma A S (NASDAQ:ASND) has risen 11.03% since March 14, 2016 and is uptrending. It has outperformed by 5.41% the S&P500.
According to Zacks Investment Research, “Ascendis Pharma A/S is a biopharmaceutical company. The company’s product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark.”
More notable recent Ascendis Pharma A S (NASDAQ:ASND) news were published by: Prnewswire.com which released: “Ascendis Pharma A/S Announces Webcast of R&D Update” on September 22, 2016, also Prnewswire.com with their article: “Ascendis Pharma A/S Appoints Scott T. Smith as Chief Financial Officer” published on August 08, 2016, Prnewswire.com published: “Ascendis Pharma A/S Reports Full Year 2015 Financial Results” on April 14, 2016. More interesting news about Ascendis Pharma A S (NASDAQ:ASND) were released by: Prnewswire.com and their article: “Ascendis Pharma A/S Initiates Phase 3 Registration Trial for TransCon Growth …” published on August 11, 2016 as well as Prnewswire.com‘s news article titled: “Ascendis Pharma A/S Reports Second Quarter 2016 Financial Results and Provides …” with publication date: August 31, 2016.
ASND Company Profile
Ascendis Pharma A/S, incorporated on October 21, 2006, is a clinical-stage biopharmaceutical company. The Firm is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Firm is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. The Company’s subsidiaries include Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma, Osteoarthritis Division A/S (Denmark) and Ascendis Pharma, and Circulatory Diseases Division A/S (Denmark).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.